drugset / Trial / NCT07306624
Nelmastobart in Combination With Docetaxel in Non Small Cell Lung Cancer
NaSingle-groupOpen-labelTreatment
Summary
A Multicenter, Phase 2 Clinical Trial Based on an Adaptive Design to Evaluate the Safety and Efficacy of Nelmastobart in Combination with Docetaxel in Patients with Advanced/Metastatic Non-Small Cell Lung Cancer Who Are Resistant or Intolerant to Platinum-based Chemotherapy and/or Immunotherapy
Timeline
- Start
- 2026-01-10
- Primary completion
- 2027-08-31
- Completion
- 2027-08-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Docetaxel | Small molecule | 75 mg/m2 | — |
| Subject | Nelmastobart | Monoclonal antibody | 800 mg | — |